Joan Bladé

53.1k total citations · 4 hit papers
324 papers, 14.8k citations indexed

About

Joan Bladé is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Joan Bladé has authored 324 papers receiving a total of 14.8k indexed citations (citations by other indexed papers that have themselves been cited), including 282 papers in Hematology, 184 papers in Molecular Biology and 158 papers in Oncology. Recurrent topics in Joan Bladé's work include Multiple Myeloma Research and Treatments (271 papers), Protein Degradation and Inhibitors (96 papers) and Peptidase Inhibition and Analysis (72 papers). Joan Bladé is often cited by papers focused on Multiple Myeloma Research and Treatments (271 papers), Protein Degradation and Inhibitors (96 papers) and Peptidase Inhibition and Analysis (72 papers). Joan Bladé collaborates with scholars based in Spain, United States and France. Joan Bladé's co-authors include Laura Rosiñol, Jesús F. San Miguel, Robert A. Kyle, Pieter Sonneveld, Juan José Lahuerta, María Teresa Cibeira, Heinz Ludwig, Mario Boccadoro, Philip R. Greipp and David H. Vesole and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Joan Bladé

315 papers receiving 14.5k citations

Hit Papers

International Staging System for Multiple Myeloma 1998 2026 2007 2016 2005 1998 2007 2022 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. International Staging System for Multiple Myeloma
    2005 1.9k citations Jesús F. San Miguel, Joan Bladé et al. Journal of Clinical Oncology profile →
  2. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
    1998 1.2k citations Joan Bladé et al. British Journal of Haematology profile →
  3. Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression
    2007 505 citations Pieter Sonneveld, Joan Bladé et al. Journal of Clinical Oncology profile →
  4. Extramedullary disease in multiple myeloma: a systematic literature review
    2022 111 citations Joan Bladé, Philippe Moreau et al. Blood Cancer Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joan Bladé Spain 61 12.1k 9.3k 6.9k 2.4k 1.0k 324 14.8k
David S. Siegel United States 59 11.3k 0.9× 10.1k 1.1× 7.6k 1.1× 1.6k 0.7× 1.2k 1.2× 415 15.8k
Michèle Cavo Italy 62 11.3k 0.9× 7.7k 0.8× 6.7k 1.0× 2.2k 0.9× 1.3k 1.3× 557 14.5k
Hervé Avet‐Loiseau France 67 12.7k 1.0× 11.3k 1.2× 7.4k 1.1× 2.7k 1.1× 1.4k 1.3× 374 17.0k
Antonio Palumbo Italy 51 9.8k 0.8× 8.0k 0.9× 5.9k 0.9× 1.5k 0.6× 1.2k 1.2× 309 12.5k
Jean‐Luc Harousseau France 69 11.0k 0.9× 8.8k 0.9× 7.0k 1.0× 2.6k 1.1× 1.5k 1.5× 319 15.8k
Michel Attal France 66 13.2k 1.1× 8.4k 0.9× 7.4k 1.1× 1.8k 0.8× 1.8k 1.8× 322 16.2k
Mario Boccadoro Italy 60 10.9k 0.9× 8.3k 0.9× 7.4k 1.1× 2.2k 0.9× 2.5k 2.5× 479 15.9k
Thierry Façon France 69 17.1k 1.4× 13.1k 1.4× 10.6k 1.5× 3.4k 1.4× 1.5k 1.5× 458 21.9k
A. Keith Stewart United States 57 7.7k 0.6× 8.0k 0.9× 4.6k 0.7× 1.5k 0.6× 940 0.9× 189 11.3k
Francis K. Buadi United States 57 7.8k 0.6× 8.7k 0.9× 4.8k 0.7× 2.3k 1.0× 661 0.7× 398 12.5k

Countries citing papers authored by Joan Bladé

Since Specialization
Citations

This map shows the geographic impact of Joan Bladé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan Bladé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan Bladé more than expected).

Fields of papers citing papers by Joan Bladé

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joan Bladé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan Bladé. The network helps show where Joan Bladé may publish in the future.

Co-authorship network of co-authors of Joan Bladé

This figure shows the co-authorship network connecting the top 25 collaborators of Joan Bladé. A scholar is included among the top collaborators of Joan Bladé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joan Bladé. Joan Bladé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rodríguez‐Lobato, Luis Gerardo, Arturo Pereira, Carlos Fernández de Larrea, et al.. (2025). Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period. Blood Cancer Journal. 15(1). 103–103. 1 indexed citations
2.
Anderson, Larry D., Joan Bladé, & Robert A. Kyle. (2024). A case of benign immunoglobulin D monoclonal gammopathy of undetermined significance with 26 years of follow‐up. SHILAP Revista de lepidopterología. 5(1). 235–237. 1 indexed citations
3.
Rodríguez‐Otero, Paula, Philippe Moreau, Meletios Α. Dimopoulos, et al.. (2024). Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.. Journal of Clinical Oncology. 42(16_suppl). 7502–7502. 9 indexed citations
4.
Rodríguez‐Lobato, Luis Gerardo, Natalia Tovar, María Teresa Cibeira, et al.. (2024). The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma. HemaSphere. 8(5). e76–e76. 3 indexed citations
5.
Lozano, Ester, Mari-Pau Mena, Glòria Garrabou, et al.. (2024). Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple Myeloma. Clinical Cancer Research. 30(17). 3944–3955.
6.
Rodríguez‐Lobato, Luis Gerardo, Natalia Tovar, Carlos Fernández de Larrea, et al.. (2023). Outcomes of Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma According to Clinical Trials Enrollment: Experience of a Single Institution. Cancers. 15(21). 5261–5261. 2 indexed citations
7.
Rodríguez‐Lobato, Luis Gerardo, Arturo Pereira, Carlos Fernández de Larrea, et al.. (2021). Real‐world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45‐year period. British Journal of Haematology. 196(3). 649–659. 7 indexed citations
8.
Lozano, Ester, Mari-Pau Mena, Tania Díaz, et al.. (2020). Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. Clinical Cancer Research. 26(17). 4688–4698. 38 indexed citations
9.
Puig, Noemí, Luís A. Corchete, Julio Dávila, et al.. (2020). Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. Cancers. 12(12). 3615–3615. 7 indexed citations
10.
Ocio, Enrique M., Paula Rodríguez‐Otero, Joaquín Martínez‐López, et al.. (2020). Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. British Journal of Haematology. 192(3). 522–530. 14 indexed citations
11.
Tovar, Natalia, Luis Gerardo Rodríguez‐Lobato, María Teresa Cibeira, et al.. (2018). Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome. Amyloid. 25(2). 79–85. 16 indexed citations
12.
Bladé, Joan, Miguel Ángel Calleja, Juan José Lahuerta, et al.. (2018). Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project. BMJ Open. 8(2). e018850–e018850. 5 indexed citations
13.
Rodríguez‐Lobato, Luis Gerardo, Carlos Fernández de Larrea, María Teresa Cibeira, et al.. (2017). Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis. Amyloid. 24(4). 238–245. 4 indexed citations
14.
Lonial, Sagar, Jesús F. San Miguel, Joaquín Martínez‐López, et al.. (2017). Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study. Blood. 130. 1869–1869. 9 indexed citations
15.
Larrea, Carlos Fernández de, Luis Gerardo Rodríguez‐Lobato, Natalia Tovar, et al.. (2017). Bone Marrow Plasma Cell Infiltration in Light Chain Amyloidosis: Impact on Organ Involvement and Outcome. Blood. 130. 5365–5365. 1 indexed citations
16.
Jiménez, Raquel, Laura Rosiñol, María Teresa Cibeira, et al.. (2017). Incidence and Outcome of Soft-Tissue Plasmacytomas in Patients with Multiple Myeloma before and after the Introduction of Novel Drugs. Blood. 130. 3140–3140. 5 indexed citations
17.
18.
Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Pilar Giraldo, et al.. (2013). Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine. 369(5). 438–447. 348 indexed citations
19.
20.
Lahuerta, Juan José, María‐Victoria Mateos, Joaquín Martínez‐López, et al.. (2008). Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. Journal of Clinical Oncology. 26(35). 5775–5782. 193 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David S. Siegel Breakdown of academic impact, for papers by Michèle Cavo Breakdown of academic impact, for papers by Hervé Avet‐Loiseau Breakdown of academic impact, for papers by Antonio Palumbo Breakdown of academic impact, for papers by Jean‐Luc Harousseau Breakdown of academic impact, for papers by Michel Attal Breakdown of academic impact, for papers by Mario Boccadoro Breakdown of academic impact, for papers by Thierry Façon Breakdown of academic impact, for papers by A. Keith Stewart Breakdown of academic impact, for papers by Francis K. Buadi
Rankless by CCL
2026